Skip to content

Celcuity CELC Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$5.33B+220%
Gilead Sciences logo
Gilead SciencesGILD
$2.54B+44.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$197.28M+1.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$51.11M+30.2%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$86.88M-30.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.4%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's operating cash flow?
Celcuity (CELC) reported operating cash flow of -$55.07M in Q1 2026.
How has Celcuity's operating cash flow changed year-over-year?
Celcuity's operating cash flow decreased by 53.6% year-over-year, from -$35.85M to -$55.07M.
What is the long-term trend for Celcuity's operating cash flow?
Over 4 years (2021 to 2025), Celcuity's operating cash flow has grown at a 65.7% compound annual growth rate (CAGR), from -$20.31M to -$153.28M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.